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Articles reporting on the chemical modifications and transformations of 3-azahetarylchroman-4-
ones are reviewed. The following transformations of 3-azahetarylchroman-4-ones including 
reduction into corresponding 3-azahetarylchromanols, -chromenes or -3,4-dihydrochromenes, 
alkylation of 3-azahetarylchromanols, reconversion of 3-azahetarylchroman-4-ones into 3-
azahetarylchromones, formation of 3-hetarylchroman-4-one oximes and corresponding oxime 
ethers, recyclization into 3-aryl-4-hetarylpyrazolines are discussed. The biological activity data for 
3-azahetarylchroman-4-one derivatives and products of their transformations is also adduced. 
 
________________________________________________________________________________ 
Introduction 
The hydrogenated chromone derivatives are of 
indubitable interest, owing to a wide spectrum 
of their biological activity (estrogenic, 
anticancer antiinflammatory, antioxidative, 
hepato-protective, antimicrobial, hypolipidemic 
et al.) [1, 2]. Being in the same molecule N-
containing heterocycles and chromone or 
chroman rings represent a useful source of 
exploratory chemistry for discovery of novel 
biologically active compounds (Figure 1). 
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Figure 1.  General formulas of chromone derivatives row 
Carrying out systematic investigation of 
chemical and biological properties of 3-
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azahetarylchromones we took into consideration 
the synthesis, chemical modification and 
transformation of hydrogenated 3-
azahetarylchromones. The small difference in 
the structure of 3-azahetarylchroman-4-ones and 
3-azahetarylchromones resulted in big 
difference in their chemistry and bioactivity.  
The up-to-date state of researches on 3- 
azahetarylchroman-4-ones’ synthesis and 
biological activity was early reflected in mini 
review [3]. The present article complements 
previous review and is dedicated to the chemical 
properties of 3-azahetarylchroman-4-ones and 
the biological activities of 3-azahetarylchroman-
4-one modification or transformation products.  
 
Results and discussion 
In the progress to determine the 
chemical potential of 3-azahetarylchroman-4-
ones and in the search for new compounds of 
pharmacological interest the following 
modifications and transformations of 3-
azahetarylchroman-4-ones were carried out. 
There are different derivatives obtained by 
hydrogenation of 3-azahetarylchromon-4-ones, 
3-azahetarylchromon-4-ones conversion 
products in reactions with nucleophiles (C-4 
modified 3-azahetarylchromon-4-ones, such as 
oximes and hydrazones derivatives or the 
cleavage products of the benzopyrane ring of 3-
azahetarylchromon-4-ones, such as isoxazoline 
and pyrazoline derivatives), the products of 
electrophilic attack by formaldehyde and 
reconversion products into 3-
azahetarylchromones.  
 
1. Synthesis of 3-azahetarylchroman-4-ols, -
chromenes and -3,4-dihydrochromenes 
 
3-Hetarylchroman-4-ones may be used as 
starting materials to obtain the corresponding 3-
hetarylchromanols, -chromenes and -3,4-
dihydrochromenes. The hydrogenated 
derivatives of 3-azahetarylchroman-4-ones were 
synthesized following classical reduction 
procedures.  
Thus catalytic hydrogenation of 3-piperidino- 
chroman-4-one hydrochloride (1) in 0,1 N HCl 
with 10% Pd on carbon powder was used to 
obtain 3-piperidinochroman-4-ol (2) [4] 
(Scheme 1). 
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Scheme 1. The synthesis of 3-piperidinochroman-4-ol 
Stereochemistry? 
In the case of 3-(imidazol-1-yl)-6-R-chroman-4-
ones (3) the reduction with NaBH4 gave a 
mixture of cis- and trans-3-(imidazol-1-yl)-6-R-
chroman-4-ols (4), which was separated on a 
silica gel chromatographic column for chlorine 
derivative. The above mixtures of chromanols 4 
by alkylation with alkyl or benzyl halides gave 
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the ethers (5, cis-trans mixture) and by 
dehydration in acidic medium yielded 3-
(imidazol-1-yl)-6-R-2H-chromenes (6), 
subsequent hydrogenation of later ones resulted 
in formation of 3-(imidazol-1-yl)-6-R-3,4-
dihydro-2H-chromene 7 (Scheme 2). 
These compounds were  undergoing 
pharmacological evaluation as hypolipaemic 
and antiatherosclerotic agents. Some of them 
show interesting activities both in vitro and in 
vivo [5]. Thus chroman-4-one 3 (R=6-Cl) and 
the corresponding chroman-4-ol 4 showed 
significant hypolipidemic activity in 
normolipemic rats. Both substances 
significantly lowered triglycerides and total 
cholesterol, the hypocholesterolemic effect 
being particularly strong on LDL so that the 
HDL/LDL ratio was markedly raised [6]. 
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Scheme 2. The synthesis of 3-(imidazol-1-yl)chroman-4-ols, corresponding ethers, chromenes and 3,4-
dihydrochromenes – Hal is not defined, what is C8H17 * HNO3?
 Alkyl and benzyl ethers 5 can be considered as 
cyclic analogues of antifungal agents such as 
miconazole and isosters of the 2-(1H-imidazol-
1-yl)-1-benzyloxytetralines (Scheme 2). The 
latest  were active in vitro against Gram-positive 
bacteria, Candida albicans and dermatophytes 
[5].  
It was found chromanols 4 retain the 
hypolipemic activity of the corresponding 
chroman-4-ones 3, but when the alcoholic group 
is alkylated (5), or when the oxygenated 
function adjacent to the imidazolyl residue is 
removed (6), the activity disappears [6]. 
3-(1-Imidazolyl)-2,3-dihydro-4H-1-benzo-
pyran derivatives of the following general 
formula 8, have been patented (Figure 2), as 
well as method of preparation, pharmaceutical 
compositions and method of using such 
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compounds to inhibit blood platelet aggregation, 
to increase total serum HDL cholesterol, to 
increase the ratio between α-lipoprotein and β-
lipoprotein total cholesterol, and/or reducing 
total serum cholesterol or serum triglycerides 
[7].  
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Figure 2. General formula of patented 3-(1-imidazolyl)-
2,3-dihydro-4H-1-benzopyran derivatives  
 
The reduction of 3-(1-imidazolyl)chroman-4-
one derivatives may be performed by treatment 
with NaBH4 in methyl or ethyl alcohol, or 
LiAlH4 in anhydrous THF, diethyl ether at 
temperature ranging from about 0°C to reflux 
temperature. It can also be used catalytic 
hydrogenation in the presence of palladium, 
platinum, platinum oxide, ruthenium or Raney-
nickel in methyl or ethyl alcohol, acetic acid, n-
hexane etc., operating at a pressure ranging 
from atmospheric pressure to about 50 
atmospheres and at temperature ranging from 
about 20° to about 100° C [7](Appropriate refs 
have to be added). The synthesis of 3-(1-
imidazolyl)-4-alkylchroman-4-ol 8 (R1=OH, 
R2=Alkyl) derivatives was carried out by 
reaction of 3-(1-imidazolyl)chroman-4-one 
derivatives with a compound RZ (Z is Li or the 
group MgHal and R is C1-C6 alkyl) in anhydrous 
n-hexane at temperature ranging from about –
60° C to about –80° C (for RLi) or in anhydrous 
diethyl ether at temperature ranging from about 
0° C to room temperature (RMgHal) [7]. Ref?  
3-(1-Imidazolyl)-2H-chromene and -3,4-
dihydro-2H-chromene derivatives of the 
following general formula 9 (Figure 3) have 
been patented and shown in some cases to be 
better inhibitory of platelet aggregation than, 
e.g. 6-chloro-2,3-dihydro-3-(1-imidazolyl)-4H-
benzopyran-4-one (3) [8]. 
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Figure 3. 3-(1-Imidazolyl)-2H-chromene and -3,4-
dihydro-2H-chromene derivatives inhibiting  platelet 
aggregation          
 
Hypolipidaemic and antiatherosclerotic 
imidazol-2-yl-derivatives of bicyclic 
compounds 10 and process for their preparation 
(Scheme 3) have also been patented [9]. 
Compounds having formula 10 and the 
pharmaceutically acceptable salts thereof have 
been proposed for use in therapy in particular 
for the prevention of the coronary heart disease. 
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Scheme 3. Hypolipidaemic and antiatherosclerotic 3-(imidazol-2-yl)-2H-chromenes and -3,4-dihydro-2H-chromenes  
 
2,6-Disubstituted 3-(imidazol-2-yl)benzopyrans 
10 with significant in vitro acyl CoA cholesterol 
acyltransferase (ACAT) inhibitory activity were 
reported (Figure 4) [10]. Studies on the 
structure-activity relations showed that 
inhibitory activity was linked to the substituent 
in position 6 of the benzopyran ring and was 
modulated by the size of lipophilic substituents 
in position 2. These compounds act in a 
noncompetitive fashion. 
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Figure 4. 2,6-Disubstituted 3-(imidazol-2-yl)benzopyran 
representatives of ACAT inhibitors (10)  
3-Pyridinylchroman derivatives 11a,b which 
posess anti-estrogenic activity, process for their 
preparation (via 12a,b) (Scheme 4) and a 
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method of treating breast cancer have been 
claimed [11]. 
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2. 3-Azahetarylchroman-4-ones conversion 
products in reactions with nucleophiles 
In general, chroman-4-one derivatives readily 
react with hydroxylamine, hydrazines, 
semicarbazides, thiosemicarbazides and other 
hydroxylamine- and hydrazine-derived 
reactants. Indeed, these type of reactions are 
Schiff base reaction which result in C=N 
formation. Isoflavanone Schiff bases of 
various structures have been patented as 
therapeutic agents for the treatment, 
prevention or amelioration of diseases 
associated with aberrant cell survival, aberrant 
cell proliferation, abnormal cellular migration, 
abnormal angiogenesis and estrogen/androgen 
balance, dysfunctional steroid genesis, 
degeneration including degenerative changes 
within blood vessel walls, inflammation and 
immunological imbalance [12]. Substituted 
N,N-dimethylaminoalkyl ethers of 
isoflavanone oxime have been claimed  as 
H1- receptor antagonists [13]. Benzoxazepine 
derivatives, obtained by isoflavanone oximes 
transformation, have been patented as 
selective estrogen receptor modulators [14].  
 
2.1. C-4 modified 3-azolylchroman-4-ones 
2.1.1. Synthesis of 3-azolylchroman-4-one 
oxime derivatives 
 
Fungal infections cause a persistent burden on 
human and animal health, plants and 
agricultural economy [15]. This rising 
incidence of fungal infections along with the 
development of resistance to current 
antifungal therapeutics continues to drive the 
search for more effective new agents. Among 
the different classes of antifungal agents 
(arylalkyl)azoles are the first-line drugs for 
the treatment of invasive fungal infections, 
because of their high therapeutic index, acting 
as sterol biosynthesis inhibitors in fungi [16] 
(Figure 5). The examination of the structure 
of well-established drugs for the treatment of 
many mycotic infections reveals the presence 
of one common pharmacophore structure, 
which is characterized by a phenyl ring linked 
by an ethane chain to a nitrogen of azole ring 
(imidazol, A=CH, or triazole, A=N) [17]. The 
ethane chain is often substituted on its C-2 by 
different groups: by ether group, as in 
miconazole; by the 1,3-spirodioxolane ring, as 
in ketonazole, or oxime ether group, as in 
oxiconazole. The role of the oxime group has 
already been examined in other fungicides 
and antifungal agents [18, 19]. Some 
azolylmethylchromanone derivatives were 
reported to posses antifungal activity [20, 21]. 
In view of the above observation and in quest 
to develop new azole antifungals Emami S. et 
al. have designed and synthesized a few series 
of 3-azolylchroman-4-one oximes (structure 
A) and oxime ethers (structure B) as 
conformationally constrained or cyclic 
analogs of well-established (arylalkyl)azole 
antifungals (Figure 5). 
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Figure 5. Antifungals, anticonvulsants and their conformationally constrained analogs 
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Two stereoselective synthetic pathways were 
used to obtain the (E)- and (Z)-3-
azolylchroman-4-one oximes [22-24].  
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MeOH
r.t.
(Z)-
R=H, Cl
Het= NN
N
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N
NN
a
b
c
14a-c (65-98 %)
13a-c
 Scheme 5. The synthesis of (Z)-3-azolylchroman-4-one 
oximes  
 3-Azolylchroman-4-ones 13a-c were converted 
to the pure (Z)-oxime derivatives (Z)-14a-c in 
good yields by stirring with 3-equiv. of 
HONH2*HCl in methanol, as illustrated in 
Scheme 5. (E)-3-Azolylchroman-4-one oximes 
(E)-14a-c were synthesized from (Z)-3-
bromochroman-4-one oxime (Z)-15]. 
Nucleophilic substitution of bromine in 
compound (Z)-15 by imidazole in DMF or 
1,2,4-triazole in the presence of K2CO3 in 
MeCN at room temperature afforded 
compounds (E)-14a-c (Scheme 6). 
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Scheme 6. The synthesis  of  (E)-3-azolylchroman-4-one oximes  
 
 
trans-3-Azolyl-2-methylchroman-4-one 
oximes (Z)-16a-c were synthesized from the 
corresponding trans-3-azolyl-2-methyl-
chroman-4-ones 17a-c to investigate the 
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influence of a methyl group at position 2 on 
chroman nucleus and to optimize the 
structure-activity relationships (Scheme 7) 
[25, 26].  
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 Scheme 7. The synthesis of (Z)-trans-3-azolyl-2-
methylchroman-4-one oximes 
 
Previously, Ji et al. designed 2-
alkylchromanone and their oximes as non-
azole inhibitors of 14α-demethylase [27]. 
In new study [28], S. Emami et al. 
incorporated imidazole ring on the 3-position 
of 2-alkylchromanones to design new 
inhibitors of 14α-demethylase and potential 
antifungal agents. It is speculated that the 
chroman ring having the 2-alkyl side chain in 
compounds A (Scheme 8) might be a mimetic 
of B and C rings or D ring and 17-alkyl side 
chain of the lanosterol and that the 3-
imidazolyl residue of A fills the position of 
the 14-methyl group of lanosterol for 
coordination binding to the heme of lanosterol 
14α-demethylase. 
 Thus, a series of 2-alkyl-3- 
imidazolylchromanones 18a-g were 
synthesized by cyclization of N-(2-
hydroxyphenacyl)imidazole derivative with 
(un)linea aliphatic aldehydes in refluxing 2-
propanol, in the presence of piperidine as a 
catalyst ( Scheme 8. The oily crude products 
(19a-g) were trans-stereoisomers, which 
underwent nitrate salt formation by using 
nitric acid in diethyl ether. The 2-alkyl-3-
imidazolylchromanone nitrates (18 a-g) were 
obtained as a pure crystalline products. For 
preparation of oxime derivatives 20 a-g, the 
crude products (19 a-g) were treated with 
excess hydroxylamine hydrochloride in 
methanol at room temperature. In this 
reaction, the addition of K2CO3 assisted to the 
reaction completion. The oxime products 
(20a-g) were assigned as (Z)-trans-
stereoisomers. The experimental data based 
on 1H NMR spectroscopy revealed that 2-
alkyl side chain and 3-imidazolyl moiety in 
compound 18d exist predominantly in the di-
equatorial conformation. While docking study 
with 14α-demethylase demonstrated that the 
di-axial form of compound 18d can be 
considered as active conformation.  
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Scheme 9. The synthesis of 3-azolylflavanone oximes 
 
 In the research field of azole antifungal 
agents investigations with a flavan core have 
been reported [29]. A series of new trans-3-
azolyl-flavans containing 4 oxo (21) or (Z)-4-
hydroxyimino (22) functional groups on the 
flavan ring were synthesized chemo- and 
stereoselectively, as potential antifungal 
agents [30-32]. The synthetic pathway to 
target compound is the reaction of 2-azolyl-
2’-hydroxyacetophenone with different 
benzaldehyde derivatives and subsequence 
oximation reaction (Scheme 9). The trans-3-
azolylflavanones 21 were obtained in good 
yields (except compound 21 (X=N, R=4-F) 
without using chromatography under fairy 
mild reaction conditions tolerating various 
functional groups. The results showed that 
0.33 equivalents of piperidine as catalyst in 
refluxing 2-propanol had good activity and 
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very high selectivity to trans-3-
azolylflavanones, while the use of acid 
medium decreased the catalytic activity and 
flavanone selectivity because of the 
production of equilibrium position between 
the four potential products (E- and Z-
chalcones and cis- and trans-flavanones). It is 
for this reason, the reaction of 2-imidazolyl-
2’-hydroxyacetophenone and benzaldehyde in 
equimolar quantities in AcOH at 90˚C for 12 
hours or in an excess of benzaldehyde at 110-
120°C for 10 hours have proved unsuccessful 
and the target trans-3-imidazolylflavanone 21 
(X=CH, R=H) was obtained with very low 
yields 12% and 14% respectively [32]. 
 
 2.1.2  Synthesis of 3-azolylchroman-4-one 
oxime ethers 
O-Alkylation of (E)- and (Z)- 3-
azolylchroman-4-one oximes (E),(Z)-14a-c 
with substituted benzylhalides 23 in the 
presence of K2CO3  in DMF at 50
0 C (for (Z)-
14a,c) or in DMF in the presence of NaH at 
room temperature (for (Z)-12b and (E)-14a-c) 
gave the corresponding (E)- and (Z)-3-
azolylchroman-4-one oxime ethers (E)-24a-c 
and (Z)-24a-c (Method A) (Scheme 10). 
Alternatively, the o-substituted oximes could 
directly be obtained from the corresponding 
3-azolylchroman-4-ones 13a-c (Method B). 
The treatment of the latter with o-
(arylmethyl)hydroxylamines 25 in methanol 
afforded a mixture of (Z)- and (E)-oxime 
ethers (Z),(E)-24a-c, predominantly in the Z 
configuration, which was established by 1H 
NMR spectra data. The Z/E ratio was 
approximately 90:10 (examples for 1,2,4-
triazolyl derivatives: (Z),(E)-24b (R1= H, 
R2=4-Cl) - 66% (Z)-24b and 8% (E)-24b; 
(Z),(E)-24c (R1= Cl, R2= 2,4-Cl2) - 46% (Z)-
24c and 5% (E)-24c as a free base). In most 
cases in the work up of the crude products of 
imidazolyl derivatives (Z),(E)-24a led to the 
practically pure (Z)-oxime ethers in moderate 
yields ( (Z)-24a (R1= R2= H) - 51%; (Z) –24a 
(R1= Cl, R2= 3,4-Cl2) - 45% ). 
 Both synthetic pathway (methods A and B) 
were used to target (Z)-trans-3-azolyl-2-
methylchroman-4-one oxime ethers (Z)-26-a-
c, which were obtained in generally good 
yields (45%-82 %) (Scheme 11).  
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Scheme 10. The synthesis of isomeric (E)- and (Z)-3-azolylchroman-4-one oxime ethers
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Scheme 11. Stereoselective synthesis of (Z)-trans-3-azolyl-2-methylchroman-4-one oxime ethers   
 
The configuration of the oximes (Z)-14a-c, 
(E)-14a-c and oxime ethers (Z),(E)-24a-c and 
(Z)-26a-c was assigned by 1H NMR 
spectroscopy. Chemical shifts of the H-3 and H-
5 protons of the chroman ring are different in 
the (E)- and (Z)-isomers of oximes and oxime 
ethers. (E)-Oximes 14a-c showed a signal at 
5.26-5.44 ppm for H-3. In contrast (Z)-oximes 
14a-c exhibited the H-3 signal at the lower field 
5.87-6,04 ppm, due to the deshielding effect of 
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the hydroxyl group on the H-3. On the other 
hand, the chemical shift of H-5 of (E)-14a-c is 
influenced by the hydroxyl group and the signal 
appeared downfield at 8.70 ppm, whereas those 
of the (Z)-isomers (Z)-14 a-c showed the same 
signal at 7.85-7.87 ppm. Similar results were 
observed in the 1H NMR of the oxime ethers 
(Z)- and (E)-24a-c.  
Thus, the configurational assignment of the 
oxime geometry was simple due to the strong 
anisotropic deshielding by the oxime oxygen on 
the H-3 or H-5 proton on chroman ring. 
Structural characterization of trans-2-methyl-3-
(1,2,4-triazolyl)chroman-4-one oxime ethers has 
been achieved [26]. By analysis of vicinal 
interproton coupling constants, it is believed 
that trans-2-methyl-3-(1,2,4-triazolyl)chroman-
4-ones which exist predominantly in the 
diequatorial half-chair or sofa conformation was 
found to exist predominantly in the diaxial 
orientation upon conversion to the 
corresponding oxime ether derivatives. 
Besides azole antifungals with benzyl ether side 
chains, omoconazole is a distinct azole 
antifungal with non-benzylic side chain namely 
2-(4-chlorophenoxy) ethyl ether. In continuation 
of research program on azole antifungals, 
modifications on the side chains of 
imidazolylchromanone oxime ethers was 
focused, and 2-phenoxyethyl ether moiety was 
attached to the imidazolylchromanone oxime 
scaffold instead of benzyl ether residue [33]. 
O
N
OH
N
N
14
(44-84 %)
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N
N
N
O
O
Cl Cl
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CH
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N
N
O Cl
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R
R
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3
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3
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*
R=H, 4-Cl, 3-Cl, 4-F, 3-F, 2,4- Cl
2  
Scheme 12. Synthesis of imidazolylchromanone O-
(phenoxyethyl) oxime ethers.  
 
The synthesis of target imidazolylchromanone 
O-(phenoxyethyl)- oxime ethers is outlined in 
Scheme 12. (E)-oxime 14 was reacted with 
phenoxyethyl chloride derivatives 27a-f in the 
presence of NaH in DMF to give (E)-oxime 
ether derivatives 28a-f. The structures of 
compounds 28a-f were fully characterized by 
IR, 1 H NMR, 13C NMR and MS spectral data.  
 
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2016, VOLUME 04, ISSUE 02)  
15 
 
2.1.3. Biological activities of 3-
azolylchroman-4-one oxime and oxime ether 
derivatives   
2.1.3.1. Antifungal activity  
A series of (E)- and (Z)-3-(1H-imidazol-1-
yl)chroman-4-one oxime ethers 24a have been 
tested for antifungal activity against pathogenic 
fungi. Oxiconazole and miconazole were used 
as reference drugs. Most compounds showed 
moderate to potent in vitro antifungal activity. 
Among the tested compounds, compound (E)-
24a (R=H, R’=3,4-Cl2) was the most active 
agent against Candida albicans and Aspergillus 
niger and compounds (Z)- and (E)-24a 
(R=R’=H) were the most potent compounds 
against Microsporum gypseum. The position 
and number of chlorine atoms at O-benzyl 
group and chlorine atom linked to the 7 position 
of chroman ring seemed to have different 
influence on the antifungal activity against 
various fungi strains. Among the test strains, 
only against Aspergillus niger, a good 
correlation between activity and the geometry of 
oxime group was observed [ 24]. 
The results of antifungal evaluation of the test 
1,2,4-triazolylchromanone oxime ethers 24b,c 
indicated that the compound (Z)-24b (R= 7-Cl, 
R’= 2,4-Cl2) was the most potent against the 
yeasts, compounds (E)-24b (R= H, R’= 4-Cl) 
and (E)-24b (R= H, R’= 4-Br) showed 
comparable or more potent antifungal activity 
with respect to fluconazole against all tested 
fungal species. Compounds (Z)-24b (R= H, 
R’= 4-Cl), (Z)-24b (R= H, R’= 4-Br) and (Z)-
24b (R= H, R’= 3-F) showed comparable or 
more potent antifungal activity with respect to 
fluconazole except for antifungal activity 
against C. albicans. Compounds (E)-24b 
(R=R’= H), and (E)-24b (R= H, R’= 3,4-Cl2) 
showed comparable or more potent antifungal 
activity with respect to oxiconazole except for 
antifungal activity against S. cerevisiae. In 
terms of structure-activity relationship, the 
1,2,4-triazol-1-yl derivatives 24b showed more 
potent antifungal activity than 1,2,4-triazol-4-yl 
derivatives 24c. In general, imidazolyl and 
1,2,4-triazol-1-yl chromanone oxime ethers 24 
have a similar biological profile and structure-
activity relationships but 1,2,4-triazol-1-
ylchromanone oxime ethers showed lower in 
vitro antifungal activity than 
imidazolylchromanone oxime ethers [23] 
The results of biological tests for antifungal 
activities of 3-azolyl-2-methylchromanone 
oxime ethers 26a-c [25, 26] demonstrated that 
the introduction of methyl group at 2-position of 
chroman ring in azolylchromanone oxime ethers 
improved the overall antifungal activity. 
Nevertheless, the effect of methyl group 
dependent on the other substituents. Many of 
the title compounds showed high activity 
against all tested fungi. Among target 
compounds, (Z)-trans-7-chloro-3-imidazolyl-2-
methylchromanone oxime ether derivative 26a 
(R= 7-Cl, R’= H) with MIC values of 0.25, 0.5 
and 1μg/mL against C. albicans , S. cerevisiae 
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and M. gypseum, showed the highest activity. 
This derivative was 32-64 times more potent 
than fluconazole and was the most potent 
among the studied 2-methyl series 26a-c. and 
nonmethyl substituted series 24a-c. Compound 
26a (R= H, R’= 4-F) was the most potent 
compounds against M. gypseum (MICs =1 
μg/mL) [25]. 
The antifungal activity of 2-alkyl-3-
imidazolylchroman derivatives 18a-g and 20a–g 
[28] were evaluated against C. albicans, S. 
cerevisiae (yeast), M. gypseum (dermatophyte) 
and A. niger (mould). In the case of C. albicans 
and S. cerevisiae trans-2-(1-pentyl)-3-
imidazolylchroman-4-one (18d) showed the 
most potent activity against yeasts with MIC 
values of 8 μg/mL comparable to fluconazole. 
Compound 18f (2-C7H15) showed good 
ingibitory activity (MICs=8–16 μg /mL) against 
yeasts comparable to fluconazole. Furthermore, 
compounds 18c (2-C4H9), 18e (2-C6H11), 20c 
(2-C4H9) and 20d (2-C5H11) were active against 
yeasts with MIC values of 16–64 μg/mL. 
Although, fluconazole was inactive against M. 
gypseum and A. niger (MICs>64 μg/mL), but 
compounds 18d–f (2-C5 - 2-C7) , 20a (2-C2H5) , 
20c–e (2-C4 - 2-C6) and 20g (2-izobutyl) 
exhibited mild activity against these fungi. The 
imidazolylchromanones (18a–c and 18g) 
containing small side chain (C1–C4) were 
inactive. While chromanones bearing longer 2-
alkyl group (>C4) showed better antifungal 
activity against all fungi strains tested. The 
comparison of chromanone compounds (18) 
with related oxime derivatives (20) 
demonstrated that oximation had negative effect 
and diminished the antifungal activity. Also, 
compounds 18g and 20g with a branched alkyl 
group (isobutyl) showed no activity against C. 
albicans, S. cerevisiae and A. niger.  
A series [33] of imidazolylchromanone oximes 
28a-f containing phenoxyethyl ether moiety 
were evaluated against yeasts (Candida albicans 
and Cryptococcus gattii) and filamentous fungi 
(Aspergillus fumigatus and Exophiala 
dermatitidis) in comparison with those of parent 
3-imidazolyl-4-chromanone oxime (14) and 
standard drugs fluconazole and itraconazole. 
The parent oxime 14 showed no activity against 
all fungal species. All title compounds 28a-f 
were inactive against C. albicans (MIC values 
>64 μg/mL). Although the title compounds 
showed marginal activity against filamentous 
fungi but all of them exhibited potent activity 
against C. gattii (MIC values = 0.5-4 μg/mL). It 
could be concluded that the phenoxyethyl ether 
scaffold is essential for antifungal activity. 
Although halogen substitution had positive 
effect in some cases depends on its position, but 
could not significantly improve antifungal 
activity. Among target compounds (3-
chlorophenoxy)ethyl analog 28c (R’= 3-Cl) with 
MIC value of 0.5 μg/ mL was the most potent 
compound, 4-8 folds more potent than other 
halo-substituted congeners against C. gattii.  
Further molecular docking studies provided a 
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better insight into the binding of designed 
compounds within the homology modeled 
active site of CnCYP51 (Cryptococcus CYP51-
14α-demethylase).  
The results of antifungal activity studies, 
together with the selectivity displayed by 
compounds 28a-f against C. gattii, introduces 
new lead compounds in the development of 
novel azole antifungal drugs for treatment of 
cryptococcal infections. Cryptococcal infections 
and specially infections caused by C. gattii are 
life-threatening complications for 
immunocompromised hosts, producing fatal 
cryptococcosis in patients who have undergone 
organ transplants and being the main cause of 
fatal meningoencephalitis in AIDS patients. 
Thus the designed compounds acting against 
this fungal pathogen are highly desirable for 
further in vivo and clinical studies. Thus, this 
compound 28c was considered for further 
molecular and computational analysis.  
Most of trans-3-imidazolyl-substituted flavan-4-
ones 21 and (Z)-trans-3-imidazolyl-substituted 
flavan-4-one oximes 22 possessed significant 
antifungal activities against the tested fungi, 
comparable or superior to fluconazole[31]. The 
modification of the 4-oxo group to oxime or 
substituent on phenyl ring produced changes in 
the antifungal activity profile of these 
compounds. Generally, in 3-imidazolyl- 
flavanone series 3’-chloro- analog 21 exhibited 
better profile of antifungal activity against 
strains of fungi tested, superior than reference 
drug fluconazole [32]. 
4’-Fluoro-analog in 3-(1,2,4-triazol-1-yl)- 
flavanone derivative 21 exhibited the best 
profile of activity against yeasts and was 4-16 
times more potent than reference drug 
fluconazole against Candida albicans and 
Saccharomyces cerevisiae. The conversion of 
flavan-4-ones to oximes (compounds 21 vs. 
compounds 22) could not improve antifungal 
activity. Among 3-(1,2,4-triazol-1-yl) flavan-4-
ones 21 compounds containing methyl or 
methoxy substituents were inactive, while 3’- or 
4’-chloro- and 3’- or 4’-fluoro- derivatives 
showed antifungal activity.  
The molecular docking study with lanosterol 
14α-demethylase, in silico toxicity risks and 
drug-likeness predictions were used to better 
define of title compounds as antifungal agents. 
The favorable drug-like property of compound 
21 makes 3-(1,2,4-triazol-1-yl)flavanone 
prototype as a promising lead for the future 
development of azole antifungal agents [30].  
 
2.1.3.2. Anticonvulsant activity 
A  series of 3-azolylchroman-4-one derivatives 
13a-c, 14a-c, 16a-c, 17a-c were explored as 
potential anticonvulsant agents. The 
anticonvulsant activity of the compounds 13a-c, 
14a-c, 16a-c, 17a-c were evaluated by 
determining seizure latency and protective 
effect against pentylenetetrazole (PTZ)-induced 
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lethal convulsions in mice at a dose of 5 mg/kg 
[34].  
Among investigated 3-azolylchroman-4-ones 
13a-c and 17a-c, 3-(1H-1,2,4-triazol-1-
yl)chroman-4-one, 7-chloro-3-(1H-imidazol-1-
yl)chroman-4-one, trans-3-(1H-imidazol-1-yl)-
2-methylchroman-4-one and  trans-7-chloro-3-
(1H-imidazol-1-yl)-2-methylchroman-4-one 
exhibited significant action in delaying seizure 
as well as effective protection against PTZ- 
induced seizure and deaths. The most effective 
compounds in delaying seizures were 3-(1H-
1,2,4-triazol-1-yl)chroman-4-one and 7-chloro-
3-(1H-imidazol-1-yl)chroman-4-one. 
Furthermore, compound 7-chloro-3-(1H-
imidazol-1-yl)chroman-4-one showed the 
maximum protection against PTZ-introduced 
mortality. No effective compound was detected 
in triazol-4-yl series. 
It found no effective compounds among 3-
azolylchroman-4-one oximes. No mortality was 
detected only with (Z)-3-(1H-imidazol-1-
yl)chroman-4-one oxime, but this compound 
afforded no significant protection against HLTE 
and delaying seizures.  
In another study [35], two distinct 
pharmacological models, lithium pilocarpine 
induced seizure and PTZ-induced kindling 
were used to investigate both anticonvulsive and 
antiepileptogenic properties of the selected 
azolylchromanones including 7-chloro-3-(1H-
imidazol-1-yl)chroman-4-one), 3-(1H-1,2,4-
triazol-1-yl)chroman-4-one, trans-3-(1H-
imidazol-1-yl)-2-methylchroman-4-one and 
trans-7-chloro-3-(1H-imidazol-1-yl)-2-methyl-
chroman-4-one in comparison to sodium 
valproate as reference drug. In spite of potent 
activity of above-cited compounds in the acute 
model of PTZ test these compounds had limited 
activity in PTZ induced kinding model. Among 
them, 7-chloro-3-(1H-imidazol-1-yl)chroman-4-
one was found to exert respectable action in 
delaying seizures and reducing seizure index at 
the dose of 10 mg/kg. These results were not 
surprising, because the two sets of models are 
fundamentally different. On the other hand, all 
tested compounds were effective in the lithium 
pilocarpine model of epilepsy. 7-Chloro-3-(1H-
imidazol-1-yl)chroman-4-one was found to be 
more effective in delaying seizures as well as 
decreasing seizure duration in this model. These 
compounds can be considered as promising and 
important class of compounds effective against 
lithium pilocarpine induced status epilepticus, 
suggesting the potential application of the test 
compounds in the treatment of status 
epilepticus. Afterwards (Z)- and (E)-oxime ether 
derivatives of imidazolylchromanones bearing 
different lipophilic O-benzyl groups 24, 26 were 
tested for their anticonvulsant activies in PTZ-
kindling model of epilepsy [36]. (Z)-O-(2,4-
Dichlorobenzyl)oximes 24 (R= 7-Cl, R’= 2,4-
Cl2), 26 (R= H, R’= 2,4-Cl2 and R= 7-Cl, 
R’= 2,4-Cl2) were significantly effective in 
delying the onset of the PTZ-evoked seizures at 
the doze of 30 mg/kg in kindled animals. The 
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most effective compounds in delying seizures 
were 7-chlorochromanone-O-(2,4-dichloro- 
benzyl) oximes 24 (R= 7-Cl, R’= 2,4-Cl2) and 
26 (R= 7-Cl, R’= 2,4-Cl2). 
 SAR studies showed that introduction of the 
chlorine atom to the 7-position and/or a methyl 
group to the 2-position of the chroman ring 
resulted in the improvement of anti-seizure 
efficacy in O-(2,4-dichlorobenzyl)oxime series. 
 
2.1.4. Synthesis of 3-azolylchroman-4-one 
hydrazone derivatives  
In continuation of research work Emami et al. 
incorporated phenylhydrazone moiety instead of 
oxime ether fragment in 3-azolylchroman-4-one 
derivatives [37]. Owing to this modification, 
based on the structure of zinoconazole, a well-
known azole antifungal possessing 
phenylhydrazone substructure, 3-
azolylchroman-4-one phenylhydrazones 29 have 
been designed and synthesized as new 
antifungal agents.  
 The synthesis of hydrazone derivative 29b 
(R= H) was first attempted by reaction of 3-
(1,2,4-triazol-4yl)chroman-4-one 13b with 
phenylhydrazine hydrochloride in refluxing 
methanol in the presence of Na2CO3 as a base, 
which resulted in poor yield with mixture of 
unknown degraded products. Since the 
condensation reactions of amines and 
hydrazines with ketones are commonly 
catalyzed by acids or bases, thus the alternative 
condition was using hydrochloride salt of 
phenylhydrazine in the absence of a base. 
Accordingly, the reaction of compound 13a,b 
and 17a with phenylhydrazine hydrochloride in 
methanol at room temperature afforded final 
compounds 29 in a mild condition (Scheme 13). 
It seems that the acid released by hydrochloride 
salt of phenylhydrazine is adequate for 
catalyzing the condensation reaction. 
Previously, the reaction of chromanone and 
flavanone derivatives with substituted 
hydrazines has been investigated in different 
conditions [38, 39]. Kállay et al. have been 
reported that the flavanone hydrazones are 
predominantly obtained under acidic conditions 
while alkaline conditions give the pyrazolines 
and the 2-hydroxychalcone derivatives due to 
the ring cleavage of the hetero ring of 
chromanone [38].
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 Scheme 13. The synthesis of 3-azolylchroman-4-one 
phenylhydrazones  
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Similarly, in experiment with 3-azolyl-4-
chromanones, the hydrazone derivatives were 
predominantly obtained under mild acidic 
conditions, but in the presence of weak base 
Na2CO3, possibly produced a mixture of 
corresponding hydrazone, acyclic N-substituted 
hydrazine and pyrazoline derivatives which was 
difficult to separate and characterize. The 
structures of compounds 29 were properly 
characterized by IR, 1H NMR or Mass 
spectroscopy as well as elemental analyses.  
 
2.1.4.1 Antifungal activity of 3-
azolylchroman-4-one hydrazone derivatives  
The in vitro antifungal activity of compounds 29 
revealed that all compounds showed good 
antifungal activity against Candida albicans, 
Saccharomyces cerevisiae and Microsporum 
gypseum with MIC values of 8–16 μg/mL. The 
antifungal activity of title compounds was 
comparable to that of standard drug fluconazole 
(MIC = 8-32 μg/mL). Parent 2-methyl-3-
imidazolylchroman-4-one (17a) showed no 
activity against Saccharomyces cerevisiae, 
Aspergillus niger and Microsporum gypseum 
(MIC >64 μg/mL) and weak activity against 
Candida albicans. The results of antifungal 
assay and docking study revealed that the 
introduction of phenylhydrazone moiety on the 
chroman ring improves the antifungal activity 
against all strains. The 2-methyl-3-imidazolyl 
derivative 29’a which showed the highest drug-
likeness and drug-score values serves as a lead 
for future development of antifungal agents. 
Docking study, in silico toxicity risks and drug-
likeness predictions were used to better define 
of title compounds as antifungal agents. 
The comparison of MIC values of triazole 
derivative 29b with its O-benzyloxime ether 
counterpart demonstrates that replacement of O-
benzyloximino moiety with hyrazone can 
increase antifungal potency. However, in the 
cases of imidazol derivatives 29a and 29’atheir 
O-benzyloximino analogs have a better profile 
of antifungal activity.  
2.2. Conformationally constrained analogs of 
N-(phenethyl)piperazinyl quinolones  
2,2,1. Synthesis of N-(2,3-dihydro-4-
hydroxyimino-4H-1-benzopyran-3-yl)-
piperazinyl quinolones  
Because of increasing prevalence of bacterial 
infections, drug-discovery efforts have been 
intensified to search for more effective and 
safety antibacterial agents with a broad 
spectrum of activity and activity against 
resistant pathogens. It is known that 
fluoroquinolones are among the most attractive 
agents in the treatment of bacterial infections. 
The presence of a piperazinyl substituent at the 
C-7 position of the quinolone nucleus improves 
the ability of the fluoroquinolones to penetrate 
the bacterial cell wall, thereby boosting its 
activity against Gram-negative bacteria and 
providing some degree of Gram-positive 
activity. In ongoing antibacterial research 
program, Emami et al. have recently developed 
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new quinolone antibacterials 34 (Figure 6) derived 
from a piperazinyl quinolone nucleus (norfloxacin 
30, enoxacin 31, ciprofloxacin 32, and levofloxacin 
33) bearing 2-hydroxyimino-2-phenylethyl moieties 
at the N-4 position of the piperazine ring and 
displaying in vitro activity against Gram-positive 
organisms comparable or higher than the respective 
parent quinolones [40, 41]. To confirm the 
assumption that the conformational restriction of 
bioactive molecules offers the possibility of 
generating structures with increased potency Emami 
et al. 
NX
F
O
N
NH
COOH
R
30 norfloxacin R=Et, X=CH
33 levofloxacin
N
F
O
N
N
COOH
O
CH
3
CH
3
31 enoxacin R=Et, X=N
32 ciprofloxacin R=cyclo-Pr, X=CH
NX
F
O
N
N
COOH
R
NOH
X=CH, N;  R=cyclo-Pr, Et X+R =
O
CH
3
NX
F
O
COOH
R
N
O
NOH
N
34 35
 
Figure 6. Structure of some piperazinyl quinolone antibacterials 
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have been introduced restrictions in the mobility 
of the 2-hydroxyimino-2-phenylethyl moieties 
of 34. Convenient strategy for the synthesis of 
N-(2,3-dihydro-4- hydroxyimino-4H-1-
benzopyran-3-yl)piperazinylquinolones 35a–d 
as conformationally constrained analogs of N-
(phenethyl)piperazinyl quinolones 34 was 
elaborated [42] (Scheme 14). The synthesis of 
target piperazinyl quinolones 35 was first 
attempted by reaction of the corresponding 3-
bromo-2,3-dihydro-4H-1-benzopyran-4-one 15 
with piperazinyl quinolone 30 and subsequent 
oximation. In the first step, different solvents, 
including DMF or MeCN were used in the 
presence of NaHCO3, which resulted in poor 
yields with unknown degraded products. The 
alternative strategy was the introduction of an 
oxime functional group onto the benzopyran 
ring in the first step, and then, a coupling 
reaction with piperazinyl quinolone. Along this 
route, stirring a mixture of compound 15 and 
three equivalents of hydroxylamine 
hydrochloride in methanol/water at room 
temperature gave 3-bromo-2,3-dihydro-4H-1-
benzopyran-4-one oxime. Reaction of the latter 
with piperazinyl quinolones (norfloxacin 30, 
enoxacin 31, ciprofloxacin 32, or N-desmethyl 
levofloxacin 33) in the presence of NaHCO3 in 
DMF at room temperature afforded N-(2,3-
dihydro-4-hydroxyimino-4H-1-benzopyran-3-
yl)-piperazinyl quinolones 35a-d in good yields. 
The stereochemistry of the oxime moiety of 
compounds 35a-d was assigned to be of E-
orientation. 
 
2.2.2 Antibacterial activity of N-(2,3-dihydro-
4-hydroxyimino-4H-1-benzopyran-3-yl)-
piperazinyl quinolones  
A synthesized series of novel quinolone agents 
bearing a particular bulky and conformationally 
constrained bicyclic substituent (2,3-dihydro-4- 
hydroxyimino-4H-1-benzopyran-3-yl- moiety) 
on the piperazine ring of 7-piperazinyl 
quinolones were evaluated against a panel of 
Gram-positive and Gram-negative bacteria. It 
was identified that incorporation of a N-(2,3-
dihydro-4-hydroxyimino-4H-1-benzopyran-3-
yl)-scaffold on the piperazine ring allows 
manipulation of selectivity and potency of 7-
piperazinyl quinolones. All target compounds 
showed significant antibacterial activity against 
Gram-positive microorganisms and possess 
MIC values in the range of 0.024 – 0.78 μg/mL 
Among all target derivatives, the ciprofloxacin 
counterpart 35c, showed a high inhibition of all 
the tested Gram-positive bacteria, superior to 
the reference drugs, and displayed antibacterial 
activity at non-cytotoxic concentrations. 
Generally, compounds 35a-d were less active 
than the reference drugs against Gram-negative 
bacteria.  
 2.3. 3-Azinylchroman-4-ones conversion 
products in reactions with nucleophiles 
2.3.1. C-4 modified 3-pyridinylchroman-4-
nes  
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Polfarmex S.A. recently patented [13] novel 
substituted N,N-dimethylaminoalkyl ethers of 
isoflavanone oxime as H1-receptor antagonists 
(Figure 7). 
 
36
O
N
R
O
N
R
R
n
 
1
2 3
 
R1 , R2  independently = H, Hal, C1_3alkyl or C1-3 
alkoxy; R3 = Ph optionally substituted by R4 , R5 = H, 
Hal, C1-3 alkyl, C1-3-alkoxy, CF3, CN, N,N-diC1-3alkyl- 
amide, carboC1-3 alkoxy, C1-3alkylsulphone groups; 
R3 = 2-, 3- or 4-pyridyl , n = 1 or 2.  
 
 Figure 7 Substituted N,N-dimethylaminoalkyl ethers of 
isoflavanone oxime as H1-receptor antagonists. 
 
The pharmaceutical composition containing 
them may be used in treatment of various 
diseases, such as asthma, hay fever, allergic 
rhinitis, atopic dermatitis, conjunctivitis, 
pruritis, and eczema, or other responses where 
histamine is released and acts on H1 receptors.  
The compound of formyla 36, in which R3 is 
pyridyl group containing nitrogen at different 
positions in the benzene ring can be obtained by 
reaction of 3-pyridylchroman-4-ones 37a-c with 
2-(dimethylamino)ethoxyamine dihydrochloride 
in mixture of pyridine and dry ethanol, as shown 
in the example of 3-(pyridin-2-yl)chromane-4-
one 37a in Scheme 15. Patent specification is 
incorporated a three-step synthesis for  3-
(pyridin-3-yl)- and 3-(pyridin-4-yl)chromane-4-
ones 37b,c, including palladium-catalyzed 
(Pd(PPh3)4) cross-coupling reaction of 3-
halogenochromone with the appropriate 
pyridinylboronic acids to isoflavone derivatives 
[43], reduction with NaBH4 in alcohol to 
isoflavan-4-ol derivatives and oxidation of the 
hydroxyl group with pyridinium chlorochromate 
(PCC) to desired compounds [44]. Pyridinyl 
derivatives 37b,c can be directly obtained by 
hydrogenation of isoflavone derivatives with a 
catalytic amount of palladium on etone [45]  
OH
O
N
O
O
N
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36a 
O
O
N
O
N
N
O
N
(40 %)
DMF
DMF DMA
Pd/C 10 %
Me
2
N(CH
2
)
2
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2
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Scheme 15 Synthesis of N,N-dimethyl-2-[[3-(2-
pyridinyl)-2,3-dihydrochromen-4-ylidene]amino]oxy-
ethanamine  
 
Another embodiment of the synthesis of the 
compounds 37b,c given in the patent [11] is 
shown in Scheme 4 . 
Note an approach to the synthesis of 3-(pyridin-
3-yl)chroman-4-one derivatives 37b through a 
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new one-step gold(I)-catalyzed annulation 
reaction [46, 47] (Scheme 16). 
OH
O
37b
O
O
N
RR
N
n-Bu
3
P
5 % AuCN, 
MW, toluene,
200
o
C, 10 min
25 %
R = H, 6-MeO, 6-F, 8-F
(23-28 %)
 
 
Scheme 16 Synthesis of 3-(pyridin-3-yl)chroman-4-one 
derivatives 
 
The attempts to synthesize 3-(pyridin-2-
yl)chroman-4-one and 3-(1-methyl-1H-
imidazol-5-yl)chroman-4-one using this 
approach were not successful, probably due to 
the reduced activities of gold(I) catalysts upon 
their coordination to the N-heteroaromatic 
alkynes. Should pay attention to the fact that 
when testing compounds 37b for anti-
proliferative effects on human breast cancer cell 
line MCF-7, compounds 6-methoxy-3-(pyridin-
3-yl)chroman-4-one and 6-fluoro-3-(pyridin-3-
yl)chroman-4-one were identified as the most 
potent aromatase inhibitors with IC50 values of 
2.5 lM and 0.8 lM. and have a great potential for 
the development of pharmaceutical agents 
against breast cancer.  
 
2.3.2. C-4 modified and C-2 transformed 3-
(2-quinolyl)chroman-4-ones   
Khilya et.al. have studied the behaviour of 7-
methoxy-6-ethyl-3-(2-quinolyl)chroman-4-one 
(38) in the reactions with nucleophilic reagents 
such as hydroxylamine, hydrazine hydrate and 
quanidine.   
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Scheme 17 Reaction products of 7-hydroxy-6-ethyl-3-(2-quinolyl)chroman-4-one with nucleophilic reagents 
It should be noted that an attempt to carry out 
the oximation reaction of this compound in 
alcohol was not succesfull, in contrast to the 
analogous reaction described for 3-azolyl- 
chroman-4-ones [25, 26]. For 7-methoxy-6-
ethyl-3-(2-quinolyl)chroman-4-one (38) the 
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reaction took place in pyridine at 130° C and the 
reaction product was isolated in 75% yield. 
Taking into account the reactivity of 
chromanone derivatives toward N-nucleophiles 
to two sites: carbonyl group and C-2 position 
and the results of studies on 3-azolylchroman-4- 
ones, it was expected the formation of 3-(2-
quinolyl)chroman-4-one oxime (39), but did not 
exclude the formation of recyclization product - 
the corresponding isoxazoline 40. To select 
from the alternative structures and to prove the 
structure of the isolated product was used NMR 
spectroscopy. In the proton spectrum of the 
alternative products should be completely 
identical spin system. That is why 1H NMR 
spectrum can not serve to establish the structure 
of the synthesized compound. To prove the 
reaction product structure two-dimensional 
spectra and spectra of heteronuclear 1H13C 
correlation were measured. On the basis of 
NMR experiments the synthesized compound 
has the structure of (Z)-7-methoxy-6-ethyl-3-(2-
quinolyl)chroman-4-one oxime (39), but one 
should note the presence of corresponding 
isoxazoline 40 in the synthesized compound 
spectrum HMBC as an impurity (5-7 %). 
The reaction of 7-methoxy-6-ethyl-3-(2- 
quinolyl)chroman-4-one (38) with hydrazine 
hydrate in ethanol had not a success, whilst in 
pyridine the reaction was complete and the 
reaction product was isolated in 70% yield. To 
determine which of the positions of the chroman 
ring was attacked by hydrazine hydrate and 
accordingly what of the alternative products 40 
or 41 was obtained two-dimensional spectra 
COSY, NOSY and spectra of heteronuclear 
1H13C correlation were measured. Combined 
application of homonuclear and heteronuclear 
correlation spectroscopy allows to reliably 
determine the structure of the synthesized 
compound as pyrazoline derivative 42. The 
reaction of 7-methoxy-6-ethyl-3-(2-
quinolyl)chroman-4-one (38) with guanidine in 
dimethylformamide was failed both in the 
presence and absence of potassium carbonate 
with heating. 
3. 3-Azolyl-3-hydroxymethylchroman-4-one 
derivatives  
An electrophilic attack of formaldehyde on 
chromanones 43 resulted in small amounts of 3-
(1H-imidazol-1-yl)-3-hydroxymethylchroman-
4-ones (44) [5]. 
44
CH
2
O
R=H, Me
O
O
N
N
R
R'
O
O
N
N
R
OH
R'
R'= H, Alk, OH, alkoxy, Hal, COOH
43
 
Scheme 18. The synthesis of 3-(1H-imidazol-1-yl)-3-
hydroxymethylchroman-4-one 
4. Reconversion into 3-azahetarychromonesl  
3-(1H-Imidazol-1-yl)chroman-4-one (13a) was 
reconverted to 3-(1H-imidazol-1-yl)chromone 
(45) by bromination with bromine in acetic acid 
and subsequent dehydrobromination in pyridine 
in 68% yield [48]. 
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Scheme 19. The synthesis of 3-(imidazol-1-yl )- 
chromone- 
Partial reconversion process 7-methoxy-6-ethyl-
3-(2-quinolyl)chroman-4-one (38) in 7-
methoxy-6-ethyl-3-(2-quinolyl)chromone was 
observed by Khilya et al. when trying acylation 
enol hydroxyl compound 38 with acetic 
anhydride in pyridine at room temperature. The 
acylation reaction not passed, starting 
chromanone 38 and about 20% of the 7-
methoxy-6-ethyl-3-(2- quinolyl)chromone were 
isolated from the reaction mixture. 
Conclusions  
In conclusion, the synthesis of 3-azahetaryl-
chroman-4-one derivatives and their chemistry 
are of great interest in the field of organic and 
medicinal chemistry. The chroman-4-one 
scaffold is an important intermediate and 
interesting building block in organic synthesis 
and design of new lead compounds in drug 
design and discovery.  
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